Seagen Stock Forecast, Price & News

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seagen in the last twelve months. There are currently 6 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Seagen stock.
View analyst ratings for Seagen or view top-rated stocks.

Wall Street analysts have given Seagen a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Seagen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Seagen is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Seagen.

Seagen Inc. (NASDAQ:SGEN) announced its quarterly earnings results on Thursday, July, 29th. The biotechnology company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.14. The biotechnology company earned $388.48 million during the quarter, compared to analysts' expectations of $355.62 million. Seagen had a trailing twelve-month return on equity of 19.02% and a net margin of 25.06%.
View Seagen's earnings history.

Seagen's stock was trading at $104.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SGEN shares have increased by 46.9% and is now trading at $153.57.
View which stocks have been most impacted by COVID-19.

15 analysts have issued 12-month price objectives for Seagen's stock. Their forecasts range from $145.00 to $254.00. On average, they expect Seagen's stock price to reach $184.75 in the next twelve months. This suggests a possible upside of 20.3% from the stock's current price.
View analysts' price targets for Seagen or view top-rated stocks among Wall Street analysts.

107 employees have rated Seagen CEO Clay B. Siegall on Glassdoor.com. Clay B. Siegall has an approval rating of 99% among Seagen's employees. This puts Clay B. Siegall in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Novavax (NVAX), Incyte (INCY), Repligen (RGEN), BioMarin Pharmaceutical (BMRN), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of SGEN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seagen investors own include NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Gilead Sciences (GILD), salesforce.com (CRM), QUALCOMM (QCOM), Tesla (TSLA), Micron Technology (MU), Netflix (NFLX) and Alibaba Group (BABA).

Seagen trades on the NASDAQ under the ticker symbol "SGEN."

Seagen's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Capital International Investors (8.69%), BlackRock Inc. (6.61%), Vanguard Group Inc. (6.56%), Price T Rowe Associates Inc. MD (3.73%), Primecap Management Co. CA (2.69%) and State Street Corp (1.77%). Company insiders that own Seagen stock include Bros Advisors Lp Baker, Charles R Romp, Charles R Romp, Clay B Siegall, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Lip Bu Tan, Marc E Lippman, Morgan E Obrien, Roger D Dansey, Srinivas Akkaraju, Todd E Simpson, Vaughn B Himes and Vaughn B Himes.
View institutional ownership trends for Seagen.

SGEN stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, Putnam Investments LLC, Millennium Management LLC, Franklin Resources Inc., Wells Fargo & Company MN, and Morgan Stanley. Company insiders that have sold Seagen company stock in the last year include Charles R Romp, Clay B Siegall, Daniel G Welch, David W Gryska, Jean I Liu, Morgan E Obrien, Roger D Dansey, Todd E Simpson, and Vaughn B Himes.
View insider buying and selling activity for Seagen or view top insider-selling stocks.

SGEN stock was bought by a variety of institutional investors in the last quarter, including Macquarie Group Ltd., Woodline Partners LP, PFM Health Sciences LP, FMR LLC, Goldman Sachs Group Inc., State Street Corp, UBS Asset Management Americas Inc., and Bank of Montreal Can.
View insider buying and selling activity for Seagen or or view top insider-buying stocks.

Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGEN stock can currently be purchased for approximately $153.57.

Seagen has a market capitalization of $27.94 billion and generates $2.18 billion in revenue each year. The biotechnology company earns $613.67 million in net income (profit) each year or $3.30 on an earnings per share basis.

Seagen employs 2,092 workers across the globe.

The following companies are subsidiares of Seagen: Cascadian Therapeutics.

Seagen was founded in 1998.

The official website for Seagen is www.seattlegenetics.com.

Seagen is headquartered at 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021.

Seagen's mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at (425) 527-4000 or via email at [email protected]